Provided by Tiger Trade Technology Pte. Ltd.

RADIOPHARM THERANOSTICS LIMITED SPON ADR EACH REP 300 ORD

2.44
+0.15006.55%
Post-market: 2.440.00000.00%19:30 EDT
Volume:48.85K
Turnover:118.03K
Market Cap:35.28M
PE:-0.64
High:2.52
Open:2.36
Low:2.30
Close:2.29
52wk High:16.25
52wk Low:2.23
Shares:14.46M
Float Shares:11.08M
Volume Ratio:0.68
T/O Rate:0.44%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-3.8088
EPS(LYR):-3.6237
ROE:-92.10%
ROA:-28.33%
PB:0.95
PE(LYR):-0.67

Loading ...

Radiopharm Theranostics Receives Positive Recommendation from Data Safety and Monitoring Committee to Advance to Cohort 4 in 177Lu-RAD202 Phase 1 HEAT Clinical Trial

GlobeNewswire
·
Aug 20

Radiopharm schedules End-of-Phase 2 meeting with FDA for RAD101

TIPRANKS
·
Aug 17

Radiopharm Theranostics To Meet with U.S. FDA to Align on Pivotal Phase 3 Trial Design for RAD 101 in Diagnosis of Brain Metastases

GlobeNewswire
·
Aug 17

Press Release: Radiopharm Theranostics Reports Business Update

Dow Jones
·
Jul 31

NASDAQ Trade Halt Continues Volatility Trading Pause at 09:37 Am

Reuters
·
Jul 24

Radiopharm announces $4.1M registered direct offering

TIPRANKS
·
Jul 24

Radiopharm Theranostics Announces Concurrent US$4.1 Million Registered Direct Offering and Up To Additional A$12.7 (US$8.9) Million Australian Placement and Share Purchase Plan

GlobeNewswire
·
Jul 24

Radiopharm Theranostics Achieves Confirmed Durable Partial Response in Ongoing Phase 1 Trial of RAD204 in Patients with Advanced Solid Tumors Post-Immunotherapy

GlobeNewswire
·
Jul 22

Radiopharm Theranostics Announces Positive Phase 2b Trial Results of RAD 101 for Diagnosis of Brain Metastases

GlobeNewswire
·
Jul 22

NASDAQ Trade Halt Halt News Pending at 07:56 Pm

Reuters
·
Jul 22

Radiopharm Theranostics Ltd : H.c. Wainwright Initiates Coverage With Buy Rating; Target Price $16

THOMSON REUTERS
·
Jun 04

Radiopharm initiated with a Buy at H.C. Wainwright

TIPRANKS
·
Jun 04

Radiopharm Theranostics Reports Business Update

GlobeNewswire
·
Apr 23

Radiopharm announces new data from Phase 0/1 HEAT trial

TIPRANKS
·
Apr 20

Radiopharm Theranostics Presents Initial Findings from Phase 1 First-in-Human HEAT Clinical Trial for 177Lu-RAD202 in HER2+ Solid Tumors at American Association for Cancer Research 2026

GlobeNewswire
·
Apr 20

Radiopharm Theranostics Advances to Cohort 3 in 177Lu-RAD202 Phase 1 Dose Escalating Clinical Trial

GlobeNewswire
·
Apr 08

Buy Rating on RADX Driven by Promising RAD 101 Phase 2b Imaging Data and Clear 2026 Clinical Milestones

TIPRANKS
·
Mar 27

Radiopharm Theranostics Achieves Primary Endpoint In 90% of Patients At Second Interim Analysis of RAD 101 Phase 2b Imaging Trial in Brain Metastases

GlobeNewswire
·
Mar 24

Analysts Are Bullish on These Healthcare Stocks: Schrodinger (SDGR), Radiopharm Theranostics Limited Sponsored ADR (RADX)

TIPRANKS
·
Mar 07

Radiopharm doses first patient in Phase 1/2a study of BetaBart

TIPRANKS
·
Feb 24